SCHEMBL13041780

SCHEMBL13041780

Cc1cccc(NC(=O)Nc2ccc(-c3cc(C4CC4)nc4c3c(N)nn4C)cc2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.64
FLT3 P36888 13/20 0.64
KIT P10721 9/20 0.61
CSF1R P07333 7/20 0.61
FLT1 P17948 6/20 0.61
FLT4 P35916 6/20 0.61
BLK P51451 4/20 0.61
AURKB Q96GD4 4/20 0.61
AURKA O14965 3/20 0.61
LYN P07948 3/20 0.61
PRKD3 O94806 3/20 0.61
RET P07949 3/20 0.61
FGFR1 P11362 3/20 0.61
RPS6KB1 P23443 3/20 0.61
AXL P30530 3/20 0.61
IRAK1 P51617 3/20 0.61
NTRK3 Q16288 3/20 0.61
HIPK4 Q8NE63 3/20 0.61
SRPK1 Q96SB4 3/20 0.61
CLK4 Q9HAZ1 3/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13041755 0.92 CSF1R (0.53) KDRFLT3KITCSF1RFLT1
SCHEMBL13041781 0.92 KIT (0.58) KDRFLT3KITCSF1RFLT1
SCHEMBL13041753 0.90 KDR (0.54) KDRFLT3KITCSF1RFLT1
SCHEMBL13041765 0.90 KDR (0.61) KDRFLT3KITCSF1RFLT1
SCHEMBL13041811 0.90 KDR (0.53) KDRFLT3KITCSF1RFLT1
SCHEMBL13041802 0.89 KDR (0.52) KDRFLT3KITCSF1RFLT1
SCHEMBL13078062 0.89 KDR (0.53) KDRFLT3KITCSF1RFLT1
SCHEMBL13041819 0.89 KDR (0.51) KDRFLT3KITCSF1RFLT1
SCHEMBL2821104 0.88 KDR (0.70) KDRFLT3KITCSF1RFLT1
SCHEMBL13041791 0.88 CSF1R (0.59) KDRFLT3KITCSF1RFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825114-B2 Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same BAYER SCHERING PHARMA AG (DE) 2010-11-02 US disclosed
US-7825114-B2 Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same BAYER SCHERING PHARMA AG (DE) 2010-11-02 US disclosed
US-20090018129-A1 SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2009-01-15 US disclosed
US-20090018129-A1 SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2009-01-15 US disclosed
WO-2007144202-A1 SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-12-21 WO disclosed
EP-1867647-A1 Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them. Bayer Schering Pharma Aktiengesellschaft (DE) 2007-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018129-A1 SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME KDR, TIE1, TEK KDR 1/4885FLT3 116/4885KIT 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.